

Index

- Abandonment, 192, 204, 250
- Abortion, 29
- Acceptance, 157
- as a coping strategy, 161, 164–168, 174
 - as part of the grief process, 180, 181
- Acquired immunodeficiency syndrome: *see* AIDS; Human immunodeficiency virus (HIV-1) infection
- Acupuncture, 249
- Adenylate cyclase, 55
- Adolescents, 259, 262
- as a high risk group, 8, 13, 35–36, 237, 243, 246
 - coping strategies in, 38–44
 - risk-reduction behavior in, 37, 65
 - risk-taking behavior in, 36–38, 43, 264
- Adrenocorticotropin hormone (ACTH), 54, 58
- AIDS, 4–5, 11, 162–165, 169, 181, 187
- behavioral modification
 - prevention education in, 7, 8, 24, 44, 65, 140
 - coping with: *see* Coping
 - ethical considerations, 19–21, 24, 25, 28–29, 123, 124, 126–134
 - financial impact, 94, 259–261
 - high-risk behavior: *see* AIDS, transmission categories
 - impact on families, 93, 94, 211–214, 263–266
 - incidence, 3, 4, 7, 9, 240–244
 - legal issues, 19, 29–30
 - myths and realities, 124–126
 - pain management, 143–144
 - physical losses associated with, 12, 14, 26, 29
 - psychological losses associated with, 12, 14, 91
 - psychosocial considerations, 12–13, 250–252
 - public health issues, 23–27
 - resource allocation, 31, 246
 - respiratory complications, 29, 153
 - social accountability in, 27
 - social considerations, 23–25, 67, 71–73, 138–139, 200
- AIDS (*cont.*)
- transmission, 8, 21, 27, 38, 137–138, 140
 - transmission categories
 - bisexual, 4, 8, 30, 131, 137, 239–244, 249, 250, 251
 - blood-transfusion-associated, 4, 15, 89, 93, 230, 239–244, 246, 251, 257, 264
 - heterosexual, 4, 47–49, 61, 64–66, 239–244
 - homosexual, 4, 8, 30, 36, 131, 137, 239–244, 249, 250
 - intravenous drug users (IVDUs), 4, 5, 7, 9, 12, 48, 49, 51, 72, , 89, 124, 137–150, 165, 230
 - among adolescents, 36–38, 43
 - among minorities, 235–239, 244, 246, 249–250, 251
 - perinatal, 61, 62, 63, 137, 230
 - sexual, 89, 124, 129, 131, 230, 236, 239–244, 246, 261
 - treatment approaches, 9, 146
 - workplace issues
 - antidiscrimination policies, 130–131, 260
 - corporate responsibility, 123, 131
 - ethical issues, 123, 124, 126–134
 - prevention strategies, 123, 131–134
- See also* Human immunodeficiency virus (HIV-1) infection
- AIDS-related complex (ARC), 126, 127, 130, 132, 138, 141, 149, 162, 250, 263
- coping strategies, 114
 - immunomodulatory effect of neurohormones in, 55
 - incidence, 4, 14, 24, 26
 - pain management, 143–144
- Alcohol, 36, 138
- use of, as a coping strategy in AIDS, 43, 138–150, 231
- Alcohol abuse, 123, 228, 229; *see also* Substance abuse
- Aldosterone, 58
- Alienation, 87, 91, 95
- Alzheimer's disease, 72

- Amphetamines, 138
- Anger, 157, 158, 192
 as a coping strategy, 160, 163
 as a reaction to AIDS, 6, 74, 107
 as part of the grief process, 172–173, 179, 180, 181, 183, 186
 associated with blood-transfusion-acquired AIDS, 251, 257
- Antidepressants, 70, 95
- Anxiety, 112, 113, 169, 143, 154, 250
 as a coping strategy, 97
 as a reaction to AIDS, 91
 effect of behavioral intervention on, 69–70, 74
 management, 147, 221
 physiological consequences, 56, 91
 reduction, 66–69
 immunomodulatory effect, 67–68
- Assertiveness training, 66, 73, 74
- Atonement, 157
- Autonomic nervous system (ANS), 53–55
- Avoidance
 as a coping strategy, 109, 112, 113
- Azidothymidine (AZT), 41, 62, 93, 125, 162, 247, 250, 252, 260, 264; *see also* Zidovudine
- Barbiturates, 147
- Bargaining, 157, 161, 163
 as a coping strategy, 157, 161, 163
 as part of the grief process, 180
- Biofeedback, 5, 68, 249
- Blood-transfusion associated AIDS: *see* AIDS, transmission categories
- Cancer, 9, 68, 72, 109, 110, 168, 247
- Caregivers, 179, 182, 186, 261
 problems of, 169–171
 professional, 198
 psychological counseling for, 251
- Catecholamines, 54, 56, 67
- Central nervous system disease, 28, 29
- Cervical intraepithelial neoplasia (CIN), 59, 60, 63, 73, 74, 75
- Cirrhosis, 9, 256
- Cocaine, 36, 51, 138, 156
- Cognitive skills training, 66, 67, 69–71, 74
- Concanavalin-A (Con-A), 54, 56
- Condoms, 132, 236, 245, 246, 261
 as an AIDS prophylactic, 3, 7, 8, 9, 24
 use among adolescents, 36, 37
- Coping, 3, 5, 12, 15, 52, 137, 145, 161, 199, 226, 231, 250
 among adolescents, 38–44
 avoidance of relationships as a strategy of, 262
 immunomodulatory influence of, 71–72
 models of, 109–111
 social support systems in, 117
 strategies, 43, 63, 74, 97, 105–117, 138–150, 157, 159–169, 185–198
 among caregivers, 170, 172
- Corticosteroids, 162
 effect on HIV-1 infection, 54–57, 67
- Corticotropin-releasing hormone (CRH), 54
- Cortisol, 54, 58, 67, 70, 72
- Cortisol-binding protein (CBP), 58
- Countertransference, 98, 101
- Crack, 51, 156
- Cyclic AMP (cAMP), 54
- Cyclic GMP (cGMP), 55
- Cytokines, 54
- Cytomegalovirus (CMV), 10, 14, 58, 59, 63, 73, 190, 193, 195
- Death
 attitudes of caregivers to, 197–198
 children's reaction to, 171–174
 emotions associated with, 42, 100–101, 106–108, 149, 184, 199, 207–209, 250
 ethical issues in, 30
 legal considerations, 208–211
 parental strategies in coping with, 172
- Dementia, 15, 164, 184, 168, 263
- Demoralization, 114
- Denial, 157, 265
 as a coping strategy, 74, 97, 107, 109, 141–142, 159–160, 162
 as a reaction to AIDS, 37, 43, 97
 as part of the grief process, 180, 181
 in substance abuse, 141–142
- Depression, 43, 112, 113, 114, 116, 143, 157, 158, 169, 171
 as a coping strategy, 163–164
 as a reaction to AIDS, 88, 94, 100, 107
 as part of the grief process, 180
 effect of behavioral intervention on, 69–70, 74
 immunomodulatory effect, 53, 56
- Despair, 87, 158

- Dexamethasone, 70
- Drug abuse, 13, 61, 65, 123, 231, 250
 as a coping strategy in AIDS, 138–150
 immunomodulatory effect, 138
See also Substance abuse
- Ear-piercing, in AIDS transmission, 8, 38
- Electroconvulsive therapy, 70
- ELISA, 127, 161, 162, 220
- Empathy, 201
- Encephalopathy, 263
- β -Endorphin, 55
- Enzyme-linked-immunosorbent assay: *see*
 ELISA
- Epinephrine (E), 54, 56
- Epstein-Barr virus, 53
- Euthanasia, 5, 183–185, 188–190, 194, 195
- Exercise, 6, 115
- Factor concentrates, 256, 259, 265
- Fatigue, 91, 114, 116
- Fear, 149, 184, 214, 250
 as a reaction to AIDS, 42, 91
 as part of the grief process, 179–184
- Gay men, 89
 psychosocial stresses, 38, 39, 43
 relationship with families, 182
See also Homosexuals
- Gay-related immune deficiency (GRID), 5
- Genital warts, 50
- Genitourinary (GU) disorders
 as cofactors in HIV-1 disease progression,
 50, 51, 63, 74, 75
 increased incidence during pregnancy, 58,
 59, 73
- Gonorrhea, 50
- Grief process, 12, 15, 97, 170, 183, 190, 251
 cultural responses, 157–159
 elements in, 156, 161, 173–174
 emotions associated with, 156–157, 172–
 173, 179–181, 183, 184, 186, 204–
 207
 phases of, in children, 171–172
 stages, 180–182
- Guilt, 101, 180
 as part of the grief process, 173–174
 in blood-transfusion-associated AIDS, 264
 survivor, 157, 173
- Hallucination, 169, 186
- Health care professionals, 87, 98, 101
- Health care providers, 142–143
 ethical dimensions of care, 21–31
 problems of, 144–146
- Helplessness, 113, 180
- Hemophilia, 4, 15, 154, 240–244, 255–266
- Hepatitis, 145, 256
- Heroin, 7, 9, 156, 239
- Herpes simplex virus (HSV), genital, 50, 53,
 58, 59, 63, 68, 70, 73
- Homeopathy, 249
- Homophobia, 21, 44, 95, 214
- Homosexuality, 89, 92
 psychosocial stresses associated with, 43,
 95–96
- Homosexuals, 4, 8, 30, 36, 39, 131, 137, 214,
 239, 249, 250
 risk-reduction behavior in, 64, 65, 75
- Hopelessness, 114, 183
- Hostility, 95, 248–249
- Human immunodeficiency virus (HIV-1)
 infection, 11, 26, 27, 35, 40, 51, 52
 antibody testing for, 3, 24, 28, 43, 201, 203
 emotional response to, 107–108
 epidemiology, 35, 48–52, 73, 88–89, 235–
 243, 245
 impact on family, 93, 94
 physiological considerations, 53–58, 63
 prevention strategies, 243–246
 psychological considerations, 88, 249–252
 psychological stress, immunomodulatory
 effect of, 106, 113, 115–116
 psychosocial dimensions, 7, 44, 251
 psychosocial stressors, 52, 53, 56–63, 74, 88
 seroprevalence, 36, 219–221
 epidemiological trends, 47–52, 235–237
 ethical considerations in testing for,
 127–130
 psychological impact, 57, 73
 stress management during, 66
 social impact, 105, 106
 treatment, 9, 146
 availability to minorities, 235, 246–249
 treatment strategies, 35, 52, 63, 66, 67,
 71–74, 226–230
 behavioral intervention, 63, 65, 67, 71–73
 immunological enhancement, 63, 67, 73,
 74
 physiological approaches, 63, 66, 67, 74

- Human immunodeficiency (*cont.*)
 psychoneuroimmunology as a, 9, 52–57,
 63, 74, 106, 115–116, 117, 146, 179
 psychotherapeutic approaches, 87–101
See also AIDS
- Human papillomavirus (HPV), 50, 59, 60, 63,
 73
- Human T-cell lymphotropic virus (HTLV-
 III), 6, 222
- Hypothalamic–pituitary adrenocortical system
 (HPAC), 54, 68, 70
- Imagery, 68, 169, 194, 228
- Imipramine, 70
- Impotence, 182
- Influenza, 4, 9
- Interferon- γ (γ -IFN), 54, 55
- Interleukin-II, 55, 62,
- Interleukins, 59
- Intravenous drug use (IVDU): *see* AIDS,
 transmission categories
- Isolation, 91, 157, 258
 self, 107
 social, 14, 71, 87, 114, 250, 258
- Kaposi's sarcoma (KS), 14, 15, 55, 60, 88, 165,
 166, 167, 190, 247
- Large granular lymphocytes, 54
- Lesbianism, psychosocial stresses, 38, 43, 183
- Leukemia, 159
- Leukocyte migration inhibitory factor, 55
- β -Lipotropin, 55
- Liver disease, 256, 263
- Loneliness, 56, 72, 171, 204
- Loss
 coping with, 168–169
 developmental, in AIDS, 100, 101
- Lung disease, 37
- Lymphoadenopathy, 222
- Lymphocyte proliferative response, 54–56, 70
- Macrophages, 54, 56
- Marijuana, 138
- Meditation, 6, 228
- met-enkephalin, 55
- Military
 containment in, 222–229
 discharge considerations, 230–232
- Military (*cont.*)
 incidence of HIV-1 seroprevalence, 36,
 219–221
 mandatory testing for HIV-1 infection, 89,
 219, 220
 peer support, 224, 226
 psychological support programs, 90, 223,
 226, 227
 rehabilitation strategies in, 229, 232
 risk-reduction behaviors, 90
 special clinical issues, 89–96, 219–233
 treatment strategies, 226–230
- Minorities, 235–252
 epidemiology, 235–237, 239–244
 risk-related behavior, 73, 230, 235–239,
 243–246, 248–251
 treatment availability to, 235, 246–249
- Mood disturbance, 117
- Morphine, 192, 239
- Natural killer (NK) cell cytotoxicity, 54–56, 58,
 68, 72
- Needle exchange programs, 27
- Neoplasias, opportunistic, AIDS-related, 60, 75
- Norepinephrine (NE), 54, 55, 56
- Opiate, 138, 143, 146
- Opportunistic infections (OIs), 89, 139, 141,
 181, 222
 in female AIDS populations, 50, 51, 52, 63,
 74, 75
- Pain, 143–144, 147
 as part of the grieving process, 179, 183, 184
- Panic attacks, 107
- Pap smears, 50, 59
- Peer influence, 37, 95, 224, 226
- Pentamidine, 162
- Phytohemagglutinin (PHA), 54, 55, 56
- Pneumonia, 9, 39, 247
Pneumocystis carinii pneumonia-associated
 (PCP), 10, 39, 52, 88, 89, 257
- Pregnancy
 effect of HIV status on, 28, 57
 incidence of, in adolescents, 36, 37
 stressors in, 57–61
- Prostaglandin, 59
- Prostitutes, 236, 246
- Protein kinase C, 55

- Recreation therapy, 227
 Rejection, 93, 95, 101, 258
 Relaxation, 116, 189, 228
 immunomodulatory effect of, 53, 68
 Resignation, 158
 Rheumatoid arthritis, 69
 Risk-reduction behavior, 61–63
 factors affecting, 64–65, 73–75
 prevention education in, 7, 8, 24, 44, 65, 140

 Self isolation: *see* Isolation, self
 Self-esteem, 95, 107, 112, 251, 262
 loss of, 93, 101, 168
 Sexually transmitted diseases (STD), 37–38, 50,
 66, 129, 132
 Sleep disturbances, 91, 114, 143, 147
 Social isolation: *see* Isolation, social
 Social support networks, 63, 66, 67, 250
 influence of, in coping, 111–115, 117
 influence of, in risk-reduction behavior, 74
 Spermicides, 261
 in AIDS-risk reduction, 246
 Stigmatization, 40, 88, 99, 250, 258
 Stress, 95, 100, 169, 228, 250
 immunomodulatory effect, 53–57, 68, 72,
 106, 109, 113, 115, 116
 impact on psychological functioning,
 109–110
 management, behavioral interventions,
 64–74, 116

 Substance abuse, 22, 123, 137–150, 165, 231
 as a high risk behavior, 91–95, 228–229; *see*
 also AIDS, transmission categories
 risk-reduction behavior in, 64, 65, 74
 Suicidal ideation, 39, 43, 88, 107, 221, 223,
 229
 Suicide, 9, 183, 192,
 as a reaction to AIDS, 29, 89–91, 100,
 107–108, 250
 Sympathoadrenomedullary (SAM) system, 54,
 68
 Syphilis, 4, 50, 59, 236, 245

 T-cell populations
 cytotoxic, 70, 71, 115
 helper (CD4+), 50, 54, 55, 56, 59, 68, 115,
 222, 229
 helper/suppressor (T4/T8) cell ratios, 54
 suppressor (CD8+), 68, 115
 Tattoo needles, in AIDS transmission, 8, 38
 Thyroid-binding globulin (TBG), 58
 Thyroxine (T4), 58
 Transference, 96, 101
 Triiodothyronine (T3), 58
 Tuberculosis, 4, 9, 10
 Tumor necrosis factor, 59

 Western blot, 127, 161, 221
 Withdrawal, 71, 157

 Zidovudine, 50, 265; *see also* Azidothymidine
 (AZT)